NYMX(Delisted)
Nymox PharmaceuticalยทNASDAQ
--
--(--)
NYMX Profile
Nymox Pharmaceutical Corporation
A biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer
Bay & Deveaux Streets, Nassau, The Bahamas
--
Nymox Pharmaceutical Corporation was established in May 1995 after acquiring all the common stock of DMS Pharmaceutical Inc. Biopharmaceuticals under the Canadian Commercial Company Act. Since 1989, Nymox Pharmaceutical Corporation has been researching and developing diagnostic methods and drugs for Alzheimer's disease and brain diseases in the elderly. The company also holds US and global patents on statins for the treatment and prevention of Alzheimer's disease. They focused on the development of NX-1207 for the treatment of BPH and low-grade localized prostate cancer. The company currently sells NicAlertTM and TobacAlertTM, which detect the use of tobacco products by testing urine or saliva. The company has a patent portfolio covering its market products, its investigational drugs, and other therapeutic and diagnostic indications.
